key: cord-0054420-oelwkljh authors: Vatansever, Hafize Seda; Becer, Eda title: Relationship between IL-6 and COVID-19: to be considered during treatment date: 2020-12-24 journal: nan DOI: 10.2217/fvl-2020-0168 sha: 029b1c3e88288d00a8702e8fe4f2885286a48a09 doc_id: 54420 cord_uid: oelwkljh The detection and control of pro-inflammatory response is crucial in the early stages of viral infection. Coronavirus disease 2019 (COVID-19) is an emerging viral disease of global concern and optimal treatment has yet to be determined. Unknown response of treatment of COVID-19 is important during patient monitoring. IL-6 is one of the key cytokines after activated macrophages. Therefore, control of systemic IL-6 levels in SARS-CoV-2 infected patients may be a parameter for COVID-19 disease. This review is focused on the induction of IL-6 after viral infections as a target molecule for monitoring cellular response. After viral infection, viral products also enhance the transcription or translation of IL-6 from cells such as fibroblast, mesenchymal, endothelial and many other cells. Therefore, the control of IL-6 synthesis and secretion may be important to inhibit its signal that affects cells. Suppression of IL-6 expression strategies can also be chosen to negatively regulate the IL-6 transcription [6, 7] . The triggering of the IL-6 and the secretion of other cytokines after viral infection cause a fatal immune reaction to the hyperactivation of T cells. After cancer immunotherapy, the same cytokine storm is also observed because of T-cell activation and a boost in IL-6 secretion [8] . Therefore, pathological IL-6 secretion is thought to be the cause of the clinical symptoms after severe disease. Based on hospitalized patient data, substantial differences in laboratory findings were found in both deceased and recovered COVID-19 patients. In two reports where COVID-19 cases in Wuhan were investigated, white blood cell and neutrophil counts were significantly increased in correlation with disease severity. Also, COVID-19 patients had persistent and more severe lymphocytopenia and thrombocytopenia. A study reported that elevated neutrophils and reduced lymphocytes were also correlated with COVID-19 disease severity and death [9, 10] . It can be suggested that a cellular level of immune deficiency state was related with poor prognosis. The pathophysiology of SARS-CoV-2 with unusually high pathogenicity has not been exactly understood. In intensive care unit patients, pulmonary and extrapulmonary organ damage such as sepsis, heart failure, acute cardiac injury, acute kidney injury, shock, acidosis, alkalosis, acute liver injury may develop [11] . Recent studies have demonstrated that increased amounts of pro B type natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), high-sensitivity troponin-I (Hs-TnI), CRP, D-dimer and prothrombin were associated with inflammationrelated cardiac problems. Additionally, these parameters were also reported as risk factors of systematic inflammation related cardiac injury and were also correlated with the risk of in-hospital death [10, [12] [13] [14] . Furthermore, acute cardiac injury and heart failure may not be major fatality risk factors of COVID-19, but they could be co-existing disease outcomes of the acute respiratory distress syndrome and respiratory failure regardless of previous cardiovascular disease history. Common laboratory abnormalities in COVID-19 patients included impaired liver and kidney function test parameters. Most patients had high concentrations of alanine aminotransferase, aspartate aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase and γ-glutamyl transpeptidase and they were markedly higher in deceased patients compared with recovered patients. On the other hand, hypoalbuminaemia was shown in COVID-19 patients. Concentrations of blood urea nitrogen, ferritin, potassium and triglycerides were significantly increased in all COVID-19 patients, but were higher in deceased patients than in recovered patients [9, 12] . Interestingly, a study reported significantly lower levels of thyroid stimulating hormone and free triiodothyronine in deceased patients than in recovered COVID-19 patients in China [9] . Cytokine storm is an interesting point in COVID-19 patients. High levels of inflammatory cytokines were observed in COVID-19 patients with more severe disease and were associated with pulmonary inflammation, lung damage and multiple organ failure [15] . A previous study showed that increased levels of pro-inflammatory cytokines in serum such as IL1β, IL6, IL12, IFNγ, IP10 and MCP1 were related with pulmonary inflammation in SARS patients [16] . Additionally, Huang et al. reported high levels of IL1β, IFNγ, IP10 and MCP1 in intensive care unit COVID-19 patients, which is probably the reason for the activated T-helper-1 (Th1) cell response [12] . Moreover, Diao et al. found that the levels of TNF-α, IL-6 and IL-10 were correlated with the severity of COVID-19 [17] . IL-6 is an important cytokine whose production is related with various inflammatory diseases. Subjects with SARS-CoV-2 had high levels of IL-6 that were correlated with patient symptomatology including pulmonary inflammation and extensive lung damage [11] . Additionally, patients with SARS-CoV-2 infection had low levels of suppressor of cytokine signaling-3, which regulates and stimulates the negative feedback mechanism of IL-6 [18] . On the same line, another study reported that IL-6 levels were higher in severe COVID-19 patients and this may be used as one of the bases for predicting the transition from mild to severe infection [19] . In particular, Diao et al. showed that COVID-19 patients in intensive care had lower CD8 + T cell counts and their total CD4 + and CD8 + T cell counts were also negatively correlated with TNF-α and IL-6 concentrations [17] . In addition, recent studies showed that higher level of IL-6, CRP and also IL-10 were more significant rather than other cytokines in critical group of COVID-19 patients [20, 21] . It can be suggested that immune dysregulation is a highly important point effects; therefore, further studies are needed to explain the IL-6 mediated cellular response during viral infections, especially COVID-19. The important role of IL-6 in host defense should always be considered in clinical practice. During COVID-19 treatments, several algorithms are used for patients who have several clinical symptoms. However, the responses of the treatment for cytokine storm, especially IL-6 production, are still unknown. Elevated systemic IL-6 levels according to COVID-19 severity should be important for determination of higher risk of disease deterioration. Therefore, monitoring of the IL-6 or targeting treatment of the IL-6 for COVID-19 positive patients may be a new target for effective treatment. Future perspective SARS-CoV-2 was recognized in Wuhan and causes severe respiratory illness in humans, called COVID-19. A large number of vaccines and drugs are under investigation against COVID-19. Some of the vaccines showed promising results. New vaccines will become possible to create an immunity against SARS-CoV-2 and will be available in the market in future months. Another important point is that COVID-19 causes pulmonary and extrapulmonary organ damage which is mainly related to cytokine storm. IL-6 is the key molecule of cytokine storm, therefore IL-6 may be a target for drug development. • IL-6 is an important cytokine with pleiotropic functions such as metabolic regulation to inflammation, auto-immunity and acute-phase response. • COVID-19 patients had high levels of IL-6 that were associated with pulmonary inflammation and extensive lung damage. • COVID-19 infection has an aggressive inflammatory response with a large amount of pro-inflammatory cytokines, known as the 'cytokine storm'. • Acute increase in circulating levels of pro-inflammatory cytokines including IL-6, IL-1, TNF-α and interferon is the reason for the cytokine storm. • IL-6 may be a therapeutic target for inhibiting the cytokine storm and cytokine storm-associated organ damage. HS Vatansever wrote the primary manuscript and scientifically checked the manuscript. E Becer contributed writing-specific section. Interleukin-6 and the acute phase response Pathogen recognition by the innate immune system The two-faced cytokine IL-6 in host defense and diseases Transmissible gastroenteritis virus infection up-regulates FcRn expression via nucleocapsid protein and secretion of TGF-β in porcine intestinal epithelial cells IL-6 in inflammation, immunity, and disease Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Clinical features of patients infected with 2019 novel coronavirus in Wuhan Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Prognostic value of NT-proBNP in patients with severe COVID-19 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 Profiling serum cytokines in COVİD-19 patients reveals IL-6 and IL-10 are disease severity predictors Chloroquine triggers Epstein-Barr virus replication through phosphorylation of KAP1/TRIM28 in Burkitt lymphoma cells Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Baricitinib as potential treatment for 2019-nCoV acute respiratory disease COVID-19: combining antiviral and anti-inflammatory treatments Current concepts in the diagnosis and management of cytokine release syndrome Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities Effective treatment of severe COVID-19 patients with tocilizumab Vademecum per la cura delle persone con malattia da COVID-19 Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Immunoglobulins and virus antibody titers: of past needs, current requirements, and future options Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia The expression of IL-6, TNF-α and MCP-1 in respiratory viral infection in acute exacerbations of chronic obstructive pulmonary disease The role of interleukin 6 during viral infections Epub ahead of print) future science group The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.